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Abstract
Background: Lupus nephritis (LN) affects up to 80% of juvenile-onset systemic lupus erythematosus patients.
Mesangial cells (MCs) comprise a third of the glomerular cells and are key contributors to fibrotic changes within
the kidney. This project aims to identify the roles of MCs in an in vitro model of LN.
Methods: Conditionally immortalised MCs were treated with pro-inflammatory cytokines or with patient sera in an
in vitro model of LN and assessed for their roles in inflammation and fibrosis.
Results: MCs were shown to produce pro-inflammatory cytokines in response to a model of the inflammatory
environment in LN. Further the cells expressed increased levels of mRNA for extracellular matrix (ECM) proteins
(COL1A1, COL1A2, COL4A1 and LAMB1), matrix metalloproteinase enzymes (MMP9) and tissue inhibitors of matrix
metalloproteinases (TIMP1). Treatment of MCs with serum from patients with active LN was able to induce a similar,
albeit milder phenotype. Treatment of MCs with cytokines or patient sera was able to induce secretion of TGF-β1, a
known inducer of fibrotic changes. Inhibition of TGF-β1 actions through SB-431542 (an activin A receptor type II-like
kinase (ALK5) inhibitor) was able to reduce these responses suggesting that the release of TGF-β1 plays a role in
these changes.
Conclusions: MCs contribute to the inflammatory environment in LN by producing cytokines involved in leukocyte
recruitment, activation and maturation. Further the cells remodel the ECM via protein deposition and enzymatic
degradation. This occurs through the actions of TGF-β1 on its receptor, ALK5. This may represent a potential
therapeutic target for treatment of LN-associated fibrosis.
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Introduction
Lupus nephritis (LN) is a severe clinical manifestation of
Systemic Lupus Erythematosus (SLE). Patients diagnosed
in childhood (< 18 years) have a higher prevalence of LN
(up to 80%) and a faster rate of damage accrual in the
kidney compared to their adult counterparts [1–4].
Flares of LN occur throughout the disease course and
each flare increases the risk of permanent damage by in-
creasing damage accrual within the kidney [5]. LN is
initiated by binding of autoantibodies to antigens
expressed by native kidney cells [6]. Mesangial cells
(MCs) express high levels of antigens that are bound by
autoantibodies, including Annexin II and α-actinin, and
thus are targets for damage in LN [7, 8]. Binding of
autoantibodies to MCs leads to rapid internalisation and
initiation of an inflammatory response, an early phase
marker of glomerulonephritis in NZB/W F1 mice [9].
The response of MCs to autoantibody binding in lupus
nephritis has been extensively studied and it has been
demonstrated that an immune response is generated.
However, the response of MCs to the inflammatory
process itself occurring within LN has yet to be fully
investigated.
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MCs comprise approximately a third of the cell popu-
lation within the glomerulus. They play important roles
in homeostasis by maintaining the structural architec-
ture of the glomerulus, producing and maintaining the
mesangial matrix, regulating the filtration surface area
and phagocytosing apoptotic cells or immune complexes
[10]. MCs are similar to smooth muscle cells but with
modified functions. They have the ability to contract
which allows them to contribute to maintaining the
structural architecture of the glomerulus and regulate
the filtration surface area, but they are also involved in
the immune response of the glomerulus [11].
In response to damage (both immune complex depos-
ition and cytokine-induced) MCs contribute to fibrotic
changes that are occurring within the glomerulus by
undergoing hypertrophy and proliferation. This has been
demonstrated both in vitro and in vivo, as well as in bi-
opsy samples taken from LN patients [12, 13]. In
addition to hyperproliferating, MCs deposit increased
extracellular matrix proteins and increase production of
matrix metalloproteinases, resulting in glomerular re-
modelling [14, 15].
This study aimed to delineate the roles of MCs in the
pathogenesis of LN using a cytokine-based, in vitro
model with cytokines known to be up-regulated in the
sera of patients with active LN [16–19]. Further this
study attempted to recapitulate this using a more
physiological model in which MCs are treated with sera
from patients with LN.
Results
Mesangial cells contribute to the pro-inflammatory
environment in lupus nephritis
As studies have previously demonstrated that MCs are
able to secrete pro-inflammatory cytokines in response
to injurious stimuli, this was assessed in an in vitro,
cytokine-based LN model. Multiplex analysis was used
to determine levels of IL-6, IL-8, IL-10, and M-CSF.
Relatively high levels of IL-6 were secreted by un-
treated MCs (5180 pg/mL [4570-5602]), this was signifi-
cantly increased in response to treatment with IL-1β
(6807 pg/mL [6349-6725]; p = 0.03) and the combined
treatment (6545 pg/mL [6381-6678]; p = 0.02) (Fig. 1a).
IL-8 was expressed at high levels under basal conditions
(2247 pg/mL [2012-2643]) and this was increased further
by treatment with the combination of cytokines (3168
pg/mL [3140-3215]; p = 0.03) (Fig. 1b). In contrast, IL-
10 was expressed at low levels in the absence of treat-
ment (5.237 pg/mL [5.237–6.18]), but this was signifi-
cantly increased in response to IFN-α (17.08 pg/mL
[16.78–18.05]; p = 0.02), IFN-γ (17.81 pg/mL [17.31–
18.5]; p = 0.001) and the combined cytokine treatment
Fig. 1 Cytokine/chemokine expression by conditionally immortalised mesangial cells following cytokine stimulation. Conditionally immortalised MCs
were treated with IL-1β, TNF-α, IFN-α, IFN-γ alone and in combination (Combo) for 24 h. Multiplex was used to assess protein levels of IL-6 (a), IL-
8 (b), IL-10 (c) and M-CSF (d). N = 5 per group, data are analysed using Friedman’s test with Dunn’s post-hoc test, * P < 0.05, **P < 0.01 and
***P < 0.001 vs control
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(19.44 pg/mL [19.08–20]; p < 0.0001) (Fig. 1c). Baseline
expression of M-CSF was below the level of detection
for the assay (and were thus set at (minimum detection
level/√2): 363.45 pg/mL); however, in response to IL-1β
treatment (4905 pg/mL [2739–10,545]; p = 0.02] and the
combination of cytokines treatment (5781 pg/mL [4218-
11,778]; p = 0.004) this significantly increased (Fig. 1d).
An attempt was made to recapitulate this effect in a
more physiological model of LN using sera from patients
with active disease (renal BILAG A/B), inactive disease
(renal BILAG D/E) and age- and sex-matched HCs.
IL-6 was expressed at relatively high levels in un-
treated MCs (2396 pg/mL [2156-2475]) and this was
significantly reduced following treatment with active
LN sera (2249 pg/mL [2214-2308]; p = 0.03) (Fig. 2a).
IL-8, however, was expressed at baseline but not af-
fected by treatment (Fig. 2b). IL-10 is expressed by
untreated MCs (62.83 pg/mL [33.61–95.29]) and fol-
lowing all treatments (except 1 active disease patient
sera) this was reduced to below the level of detection
for the assay (Fig. 2c). M-CSF was expressed by un-
stimulated MCs (528.1 pg/mL [381.6–829]) and this
was significantly increased in response to treatment
with sera from active disease patients (1090 pg/mL
[835.2–1616]; p = 0.04) (Fig. 2d).
In order to exclude the sera as the source of the cyto-
kines the levels of each cytokine were assessed in RPMI +
10% sera (to mimic that which was used to treat the cells);
IL-6 and IL-8 levels in RPMI + 10% sera were below the
level of detection for all groups (data not shown). IL-10
was expressed in patient sera, in all groups this was re-
duced to below the level of significance following treat-
ment of MCs (Fig. 2e). M-CSF on the other hand was
relatively lowly expressed in active disease patient sera
(121.7 pg/mL [92.49–192.3]) and this was significantly in-
creased in MC conditioned media following treatment
(1090 pg/mL [835.2–1616]; p < 0.0001). Further M-CSF
was relatively lowly expressed in healthy control (HC) sera
(320.7 pg/mL [114.3–376.6]) and this was significantly in-
creased in conditioned media following 24 h treatment
(608.4 pg/mL [356.7–1467]; P = 0.016) (Fig. 2f).
The lupus nephritis pro-inflammatory environment
contributes to extracellular matrix remodelling by the
mesangial cells
MCs are heavily involved in maintenance of the ECM
and in response to damage secrete proteins and en-
zymes that restructure the matrix. The expression of
genes involved in remodelling the ECM were assessed
in response to 24 h cytokine treatments. MCs
expressed low levels of COL1A1 mRNA at baseline
(0.708 [0.262–1.96]) and this was significantly in-
creased in response to treatment with IFN-γ (5.089
[0.169–7.484]; p = 0.03) and the combination of
cytokines (4.951 [4.299–6.628]; p = 0.03) (Fig. 3a).
Relatively low levels of mRNA for COL1A2 were
expressed by untreated MCs (0.0002 [0.0001–0.0003]),
this was significantly increased in response to IFN-α
(0.0006 [0.0003–0.001]; p = 0.03), IFN-γ (0.0006
[0.0003–0.001]; p = 0.04) and the combination of cy-
tokines (0.006 [0.0002–0.001]; p = 0.03) (Fig. 3b).
COL4A1 mRNA was expressed at low levels in con-
trol MCs (1.428 [0.945–2.335]), this was significantly
increased by treatment with IL-1β (4.021 [2.375–
7.703]; p = 0.05), TNF-α (4.195 [3.144–6.859]; p =
0.03), IFN-γ (6.331 [2.398–9.013]; p = 0.03) and the
combination of cytokines (5.453 [3.908–8.688]; p =
0.02) (Fig. 3d). MCs expressed low levels of LAMB1
mRNA under baseline conditions (0.002 [0.001–
0.008]), this was significantly increased in response to
treatment with IL-1β (0.019 [0.013–0.028]; p = 0.05)
and the combination of cytokines (0.025 [0.022–
0.029]; p = 0.002) (Fig. 3e). MCs expressed mRNA for
COL3A1 and LAMB2 however these were not affected
by treatment (Fig. 3c and e).
In order to obtain a clear representation of the re-
modelling of the ECM it is important to assess the
expression of ECM protein genes, MMPs and TIMPs.
MCs have been shown to express MMP2 and MMP9,
as well as TIMP1 [20, 21] and thus these were
assessed following cytokine stimulation. Relatively low
levels of MMP9 mRNA were expressed by untreated
MCs (0.0001 [0.00006–0.0003]), this was significantly
increased in response to treatment with IL-1β (0.0016
[0.0015–0.0019]; p = 0.01), TNF-α (0.0015 [0.0014–
0.0019]; p = 0.02) and the combination of cytokines
(0.0016 [0.0013–0.0019]; p = 0.03) (Fig. 4a). TIMP1
was expressed at relatively high levels in control MCs
(0.564 [0.526–0.595]), this was significantly decreased
in response to IFN-γ (0.178 [0.116–0.215]; p = 0.01)
and the combination of cytokines (0.139 [0.106–
0.172]; p = 0.01) (Fig. 4c). MMP2 mRNA was also
expressed by MCs but was not significantly affected
by any of the treatments (Fig. 4a).
This was recapitulated in the more physiological
model of treating with RPMI (+ 10% patient sera). MCs
expressed mRNA for COL1A1 and COL3A1 under
normal conditions and these were not significantly mod-
ulated following treatment with 10% LN patient sera
(Fig. 5a and c). Prior to treatment COL1A2 mRNA was
expressed at relatively low levels (0.00065 [0.00022–
0.0024]), this was significantly increased in response to
treatment with active sera (0.0012 [0.0003–0.003];
p = 0.03) while inactive and HC sera had no effect
(Fig. 5b). COL4A1 mRNA was expressed by untreated
MCs (0.933 [0.181–2.307]), a trend was seen towards
an increase with active sera (1.947 [1.397–4.028]; p =
0.07) however this did not reach significance. No
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other treatments induced a change in COL4A1 mRNA
(Fig. 5d). MCs express mRNA for LAMB1 and
LAMB2 however these were not affected by any of
the sera treatments (Figs. 5e-f).
Levels of mRNA for remodelling enzymes were also
assessed. MMP2 and TIMP1 mRNA were expressed by
untreated MCs but levels were not affected by any of the
sera treatments (Fig. 6a and c). MMP9 mRNA was
expressed by MCs under normal conditions (0.000078
[0.000011–0.00022]) and this was significantly increased
by treatment with sera from active LN patients (0.00045
[0.00026–0.00071]; p = 0.011), no other treatments in-
duced any changes in MMP9 mRNA (Fig. 6b).
Extracellular matrix remodelling by mesangial cells is
induced by TGF-β1
One of the most common mediators of ECM remodel-
ling is transforming growth factor (TGF)-β1 therefore
the expression of latent TGF-β1 following cytokine
stimulation was assessed in our model. As we were keen
to investigate the role of TGF-β1 in inducing the
changes seen at 24 h the levels were assessed at 4 h and
24 h to look at temporal modulation. At 4 h post-
cytokine stimulation latent TGF-β1 was expressed at
relatively high levels (1201 pg/mL [1129-1257], this was
significantly increased following treatment with IL-1β
(2028 pg/mL [1984-2051]; p = 0.02), IFN-γ (2,076 pg/mL
Fig. 2 Cytokine/chemokine expression by conditionally immortalised mesangial cells following stimulation with lupus nephritis patient sera. Conditionally
immortalised MCs were treated with 10% sera from patients with active (rBILAG A/B) and inactive (rBILAG D/E) LN and with age-and sex-matched
HCs for 24 h. ELISA was used to assess protein levels of IL-6 in conditioned media (a) IL-8 in conditioned media (b), IL-10 in conditioned media
(c), and M-CSF in conditioned media (d). IL-10 levels in sera (black bar) and conditioned media (grey bar) (e), and M-CSF levels in sera (black bar)
and conditioned media (grey bar) (f). N = 5–6 per group, data are analysed using Kruskal-Wallis test with Dunn’s post hoc test, *P < 0.05 and
***P < 0.001 vs untreated MCs
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[1963-2096]; p = 0.02) and the combination of cytokines
(2589 pg/mL [2152-2721]; p = 0.0001) (Fig. 7a). At 24 h
however, latent TGF-β1 was expressed by untreated
MCs (873.5 pg/mL [443.4–1130], but this was decreased
following treatment with IFN-α (340 pg/mL [280.4–
679.8]; p = 0.05), IFN-γ (400.7 pg/mL [285.2–438]; p =
0.02) and the combination of cytokines (391.3 pg/mL
[151.5–561.7]; p = 0.03) (Fig. 7b).
As MCs treated with patient sera appeared to have a
milder phenotype than those treated with cytokines the
levels of latent TGF-β1 were assessed only at 24 h. When
MCs were treated with patient sera for 24 h there was a
significant increase in the production of latent TGF-β1
by MCs treated with active sera (1897 pg/mL [1515-
2010]; p = 0.014) compared to untreated MCs (941.1 pg/
mL [449.9–1150]) while no other treatments had a sig-
nificant effect (Fig. 7c). The expression of latent TGF-β1
in RPMI (+ 10% patient sera) was also assessed and it
was determined that although no significant difference
in the expression was seen between the groups this was
similar to that seen in conditioned media following MC
stimulation (Fig. 7d).
Fig. 3 Expression of mRNA for ECM genes by conditionally immortalised mesangial cells following cytokine stimulation. Conditionally immortalised
MCs were treated with IL-1β, TNF-α, IFN-α and IFN-γ alone and in combination (Combo) for 24 h. mRNA expression was assessed for COL1A1 (a),
COL1A2 (b), COL3A1 (c), COL4A1 (d), LAMB1 (e) and LAMB2 (f). N = 5 per group, data are analysed using Friedman’s test with Dunn’s post-hoc test,
*P < 0.05 and **P < 0.01 vs control
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TGF-β1 receptor activity blockade was induced by
pre-treatment with SB-431542 and following this MCs
were treated with the combination of cytokines treat-
ment (IL-1β, TNF-α, IFN-α and IFN-γ) for 24 h as previ-
ously and the expression of mRNA for ECM genes was
assessed. As demonstrated previously the combination
of cytokines induced increased expression of mRNA for
COL1A1, COL1A2, COL4A1, LAMB1, MMP9 and
TIMP1. MCs express mRNA for COL1A1 at baseline
(0.0009 [0.0002–0.005]) and this is significantly in-
creased following stimulation with the combination of
cytokines (0.01 [0.005–0.012]; p = 0.02). Pre-treatment
with SB-431542 was able to reduce this close to baseline
levels (0.002 [0.0005–0.005]) (Fig. 8a). COL1A2 mRNA
is also expressed by MCs at baseline (0.1213 [0.0168–
0.2257]) and again this is significantly increased in re-
sponse to the combination of cytokines (0.6297 [0.4857–
0.7428]; p = 0.02), again this was reduced to similar to
baseline levels by pre-treatment with SB-431542 (0.0858
[0.0387–0.1071]) (Fig. 8b). Untreated MCs express
mRNA for COL4A1 (0.7654 [0.7259–1.255]) and this is
significantly increased in response to the combination of
cytokines (2.501 [1.016–4.212]; p = 0.009), this was
unchanged compared to control following pre-treatment
with SB-431542 (0.9711 [0.8184–1.515]) (Fig. 8c).
LAMB1 mRNA is expressed by untreated MCs (0.004
[0.0003–0.018]) and trended towards an increase follow-
ing treatment with the combination of cytokines (0.1551
[0.098–0.243]; p = 0.08), levels returned to baseline fol-
lowing pre-treatment with SB-431542 (0.005 [0.0015–
0.0076]) (Fig. 8d). The expression of mRNA for MMP9
was also assessed – this was at relatively low levels
at baseline (0.005 [0.0001–0.018]) and was signifi-
cantly increased following stimulation with the com-
bination of cytokines (0.024 [0.014–0.0369]; p =
0.047) and again, this was reduced following pre-
treatment with SB-431542 (0.001 [0.0002–0.0165])
(Fig. 8e). Finally, the expression of mRNA for TIMP1
was assessed – this was expressed by untreated MCs
(20.84 [11.3–23.93]). Although it appears that a de-
crease in expression can be seen following treatment
with the combination of cytokines this did not reach
significance (9.754 [3.178–14.41]; p = 0.6). Following
pre-treatment with SB-431542 the levels appeared
closer to that seen in the untreated cells (20.47
[16.54–36.94]) (Fig. 8f).
Fig. 4 Expression of mRNA for remodelling enzymes genes by conditionally immortalised mesangial cells following cytokine stimulation. Conditionally
immortalised MCs were treated with IL-1β, TNF-α, IFN-α and IFN-γ alone and in combination (Combo) for 24 h. mRNA expression was assessed for
MMP2 (a), MMP9 (b), and TIMP1 (c). N = 5 per group, data are analysed using Friedman’s test with Dunn’s post-hoc test, *P < 0.05 vs control
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Discussion
LN is a severe manifestation of juvenile-onset SLE and
is, alongside infection and cardiovascular disease, a
major cause of SLE-associated morbidity and mortality
in these children [3]. MCs are important contributors to
the fibrotic damage seen in glomerular diseases as they
respond to injurious stimuli by proliferating and produ-
cing increased levels of ECM proteins [12–15]. Delineat-
ing the path by which these changes occur may unveil
new avenues for investigation in LN therapy.
To mimic the inflammatory environment of the LN
kidney in vitro a model was designed using key cytokines
known to be upregulated in the sera of patients with ac-
tive LN compared to inactive disease and HCs [16–19].
The contribution of MCs to the inflammatory milieu
within the kidney was investigated by assessing the levels
of pro-inflammatory cytokines and chemokines pro-
duced by MCs in response to the in vitro model. This
study demonstrated that MCs express IL-6, IL-8 and IL-
10 under normal conditions. This correlates with previ-
ously published data that demonstrated that IL-10 is es-
sential for maintaining homeostasis within the kidney
[22] and low levels of IL-6 and IL-8 are expressed by
MCs in vitro [23, 24]. In response to the cytokines in
Fig. 5 Expression of mRNA for ECM genes by conditionally immortalised mesangial cells following stimulation with lupus nephritis patient sera.
Conditionally immortalised MCs were treated with 10% sera from patients with active (rBILAG A/B) and inactive (rBILAG D/E) LN and with age-and
sex-matched HCs for 24 h. mRNA expression was assessed for COL1A1 (a), COL1A2 (b), COL3A1 (c), COL4A1 (d), LAMB1 (e) and LAMB2 (f). N = 5–6
per group, data are analysed using Kruskal-Wallis test with Dunn’s post-hoc test, *P < 0.05 vs untreated MCs
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our model, the levels of all three cytokines significantly
increased. High levels of IL-6, IL-8 and IL-10 are im-
portant for the recruitment and maturation of neutro-
phils, B cells and T cells to the glomerulus [25]. In this
model, M-CSF was not expressed/very lowly expressed
by untreated MCs but was released at high levels follow-
ing inflammatory stimulation. M-CSF is involved in the
recruitment and maturation of macrophages [25]. It is
important to note that a previous study in murine pri-
mary cells demonstrated IL-6 and IL-8 levels of approxi-
mately 80 pg/mL and 75 pg/mL respectively [24].
However, this discrepancy with our findings can be ex-
plained by the different cell type analysed. These data
demonstrate that in response to inflammatory activation,
MCs are potentially playing an important contributory
role in the recruitment and activation of immune cells
from the circulation, and thus exacerbating the inflam-
matory response seen.
Further, a more physiological model was used in which
sera from patients with LN were used to stimulate MCs
and the cytokine levels assessed. This demonstrated that
serum treatments were unable to recapitulate the in-
crease in IL-8 seen following cytokine stimulation. Ac-
tive serum was able to induce an increase in M-CSF
secretion compared to untreated MCs while no other
treatments had an effect suggesting that something
within the active sera was able to induce this secretion
that was not present in the other groups. M-CSF levels
in the sera were not different between groups. IL-6 and
IL-10 were reduced in response to serum treatments, IL-
6 levels were below the level of detection for the assay in
all sera tested so it is unclear how these may differ be-
tween groups. IL-10, however, did not differ between pa-
tient groups and all groups reduced MC secretion
suggesting that the IL-10 present in the sera may be
binding MCs and initiating a negative feedback response,
reducing the secretion from MCs.
One of the main known roles of MCs in glomerular
injury is the induction of pro-fibrotic changes by remod-
elling of the ECM. This study identified an increase in
the expression of genes responsible for the deposition of
ECM proteins in response to the in vitro, cytokine-based
model of LN. Increases in COL1A1, COL1A2 and
COL1A4 confirm that enhanced deposition of both
healthy (type IV) and pathogenic (type 1) collagens are
occurring in this model. This mimics what is seen in
lupus-prone mice (NZBWF1/J mice) where increased
type 1 collagen is seen to be deposited in the early stages
of glomerulonephritis development [26] and in graft-vs-
host disease where early deposition of type IV collagen
Fig. 6 Expression of mRNA for remodelling enzymes genes by conditionally immortalised mesangial cells following stimulation with lupus nephritis
patient sera. Conditionally immortalised MCs were treated with 10% sera from patients with active (rBILAG A/B) and inactive (rBILAG D/E) LN and
with age-and sex-matched HCs for 24 h. mRNA expression was assessed for MMP2 (a), MMP9 (b), and TIMP1 (c). N = 5–6 per group, data are
analysed using Kruskal-Wallis test with Dunn’s post-hoc test, *P < 0.05 vs untreated MCs
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is seen [27]. Increased collagen IV deposition has also
been seen in the mesangium in human LN biopsies [28].
Further increased deposition of LAMB1 is occurring,
laminin β1 has been shown to be increased in a model
of graft-vs-host disease in early disease but then reduces
as disease progresses [29], increased laminin deposition
was also seen in two of five human LN biopsies [28]. It
is important to note that in the mouse model laminin
deposition occurred only early in disease course and it is
unclear at what stage of a flare a biopsy would have been
taken in the human disease cohort.
When the MCs were treated with LN patient sera
there were significant increases noted for active disease
sera in collagen I and a trend towards an increase in
collagen IV, this suggests that similar changes may be
occurring but that these are milder than that seen with
cytokines. This may be due to the low concentration of
serum used (10%) compared to that seen in blood (45–
50%) or potentially due to the immunosuppressant treat-
ment regimens being followed by the patients (Table 1).
ECM remodelling is a combination of the increased
deposition of proteins and increased enzymatic break-
down of these proteins. Therefore, we looked at the
mRNA levels of the main enzymes involved in MC re-
modelling – MMP2 and MMP9, no significant changes
in the expression of MMP2 were noted but MMP9 levels
were significantly increased in response to treatment
with IL-1β and TNF-α. This correlates with a study that
demonstrated that at the onset of proteinuria in lupus-
prone (NZBxNZW F1) mice there is an increase in pro-
teolytic activity that can be attributed to MMP9 expres-
sion [14]. Further a decrease in the expression of TIMP1
(an MMP inhibitor) was seen with IFN-α and the com-
bination of cytokines treatment suggesting that overall
there is a net increase in the activity of these degradation
enzymes.
Fig. 7 Production of latent TGF-β1 by conditionally immortalised mesangial cells following stimulation with cytokines or lupus nephritis patient sera.
Conditionally immortalised MCs were treated with IL-1β, TNF-α, IFN-α and IFN-γ alone and in combination (Combo) for 4 and 24 h. Or with 10%
sera from patients with active (rBILAG A/B) and inactive (rBILAG D/E) LN and with age-and sex-matched HCs for 24 h. Levels of latent TGF-β1
were assessed in conditioned media from 4 h cytokine treatments (a), 24 h cytokine treatments (b), 24 h sera treatments (c) and directly in the
sera (black bar) compared to conditioned media from sera treatments (grey bar) (d). N = 5–6 per group, data are analysed using Friedman’s test
(cytokine treatments) or Kruskal-Wallis test (sera treatments) with Dunn’s post-hoc test, *P < 0.05 vs control (a,b) or MC (c)
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Fig. 8 Expression of mRNA for ECM genes by conditionally immortalised mesangial cells following cytokine stimulation with TGF-β1 receptor blockade.
Conditionally immortalised MCs were treated with SB-431542 for 30 mins before stimulation with a combination of TNF-α, IL-1β, IFN-α and IFN-γ.
mRNA expression was assessed for COL1A1 (a), COL1A2 (b), COL4A1 (c), LAMB1 (d), MMP9 (e) and TIMP1 (f). N = 5 per group, data are analysed
using Friedman’s test with Dunn’s post-hoc test, *P < 0.05 and **P < 0.01 vs untreated MCs
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These changes in enzymes were also assessed in
MCs following sera treatments and the increase in
MMP9 was recapitulated following treatment with
active sera while no changes in MMP2 or TIMP1
could be detected.
One of the main drivers of fibrosis is TGF-β1 therefore
we looked at levels of TGF-β1 in each of our models to
determine whether this could be driving the fibrotic
changes we are seeing. At 4 h post-cytokine treatment a
significant increase in latent TGF-β1 could be seen and
this was decreased at 24 h suggesting the TGF-β1 may
be being internalised and eliciting downstream effects. It
has previously been shown that in rat mesangial cells
TGF-β1 is an autocrine mediator of fibrotic change [30]
and thus could explain this temporal modulation. As it
was found that the LN patient sera treatments induced a
milder phenotype the expression of latent TGF-β1 was
only assessed at 24 h where it was shown to be signifi-
cantly increased in response to treatment with sera from
patients with active disease (renal BILAG A/B). This
may suggest that the response to sera treatments is de-
layed compared to that of cytokine treatments. To differ-
entiate between de novo production of TGF-β1 and
levels already present in the sera an ELISA was
performed to determine the concentration of latent
TGF-β1 in RPMI (+ 10% patient sera). Levels were found
to be almost identical to that seen in the conditioned
media from MCs. When considering that MCs them-
selves produce approximately 1 ng/mL TGF-β1 this may
suggest that a reduction is occurring through internalisa-
tion or that a negative feedback loop is occurring due to
the expression of TGF-β1 in the sera.
MCs express ALK5 and through this receptor TGF-β1
can induce downstream ECM remodelling [31]. An
ALK5 blocker SB-431542 was used to inhibit the effects
of TGF-β1 in this model and was able to attenuate all
ECM remodelling genes previously shown to be up-
regulated in our model following cytokine treatment
suggesting that this remodelling is occurring via TGF-β1
activity.
Given that mesangial cells do not show increased ex-
pression of these markers in response to human sera we
are unable to demonstrate the use of TGF-β1 blockade
using SB-431542 in a more physiological model, one fu-
ture possibility may be to demonstrate that mesangial
cells show increased expression of these markers in hu-
man kidney tissue, such as from kidney biopsies for pa-
tients with lupus nephritis or explore mouse models.
Table 1 Demographics, renal BILAG scores and medications for LN patients
Demographics Active LN (n = 6) Inactive LN (n = 6) Healthy Controls (n = 6)
Age (years) (median [range]) 15.53 [12.18–16.58] 14.55 [11.03–17.79] 14.9 [12.12–16.6]
Age at diagnosis (years) (median [range]) 12.8 [6.28–13.29] 10.46 [6.28–16.88] –
Females (%) 100 (6) 100 (6) 100 (6)
Nationality % (n)
White British 16.6 (1) 33.3 (2) 100 (6)
Chinese 16.6 (1) 16.6 (1) 0
Somali 33.3 (2) 33.3 (2) 0
African 16.6 (1) 16.6 (1) 0
Indian 16.6 (1) 0 0
Renal BILAG domains
Renal Hypertension (%) n 16.6 (1) 0 –
Urine ACR (mg/dL) (median [range]) 239.3 [0.7–592.4] 7.5 [0.8–8.8]
Renal Creatinine (mg/dL) (median [range]) 45 [37–62] 51 [30–61]
Estimated GFR (mL/min/1.73m2) (median [range]) 138 [99.8–158.1] 121.5 [99.1–181.9]
Medications (n)
Hydroxychloroquine 4 3 –
Azathioprine 0 3
Mycophenolate mofetil 6 3
Prednisolone 5 5
Methotrexate (oral) 0 0
Rituximab 1 0
Cyclophosphamide 1 0
ACR Albumin creatinine ratio, GFR Glomerular filtration rate
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Conclusion
In conclusion, our cytokine-based in vitro model of LN in-
duced an increase in mediators involved in eliciting an in-
flammatory response within the glomerulus and further
promoted ECM remodelling by increasing the expression of
genes involved in protein deposition and enzymatic degrad-
ation. Treatment of MCs with patient sera was able to in-
duce a similar, albeit milder phenotype. This could be
inhibited by blocking TGF-β1 receptor activity, potentially
identifying the inhibition of TGF-β1 activity as a potential




All recombinant cytokines were purchased from Pepro-
tech, London, UK. All primers were purchased from
Eurofins Genomics, Ebersberg, Germany.
Human conditionally immortalised mesangial cell culture
Human conditionally immortalised MCs were kindly pro-
vided by Professor Moin Saleem (Children’s Renal Unit
and Academic Renal Unit, University of Bristol, South-
mead Hospital, Bristol, UK). These cells were condition-
ally immortalised using the temperature sensitive large T
antigen-SV-40 transgene as previously described [32].
These cells have been shown to differentiate fully by 7–10
days after switching from 33 °C to 37 °C. Cell passages be-
tween 15 and 30 were used in all experiments, for all ex-
periments n = 5–6 independent experiments were used.
MCs were routinely cultured in RPMI-1640 medium with
L-glutamine (Lonza, Leeds, UK) supplemented with 10%
foetal calf serum (ThermoScientific) and insulin transfer-
rin selenium (Sigma-Aldrich, Dorset, UK).
After 7–10 days of differentiation conditionally immor-
talised MCs were treated with cytokines designed to
model the inflammatory environment of the kidney in
LN patients, namely: IL-1β, TNF-α, IFN-α and IFN-γ
(all known to be involved in the pathogenesis of LN) at
10 ng/mL each alone and in combination (i.e. 10 ng/mL
each of IL-1β, TNF-α, IFN-α and IFN-γ altogether).
These were chosen as being key cytokines known to be
upregulated in the sera of patients with active LN com-
pared to inactive disease and healthy control [16–19].
Following 24 h incubation conditioned media were col-
lected, and RNA was extracted using Trizol
(ThermoScientific).
Upon routine clinical visits, patients within the UK
JSLE Cohort Study are assessed according to the British
Isles Lupus Assessment Group (BILAG) 2004 index [33,
34]. Following differentiation MCs were also treated with
10% sera from patients with active LN (renal BILAG A/
B), inactive LN (renal BILAG D/E) and age- and sex-
matched HCs (Table 1). Following 24 h incubation con-
ditioned media were collected, and RNA was extracted
using Trizol (ThermoScientific).
Cells were pre-treated for 30 mins with SB-431542
(ALK5 receptor blocker) to inhibit TGF-β1 binding as
previously described [35] before stimulation with the com-
bined cytokine treatment. Following this conditioned
media was collected and RNA was extracted using Trizol.
Multiplex
A Luminex magnetic bead assay was purchased from
R&D Systems, Abingdon UK which was able to detect
IL-6, IL-8, IL-10 and M-CSF. The assay was performed
on conditioned media collected from cells treated with
cytokines for 24 h according to manufacturer’s instruc-
tions to assay protein levels in conditioned media from
cytokine-treated MCs. The plate was read using a Merck
Millipore Luminex MAGPIX® analyser.
ELISA
TGF-β1, IL-6, IL-8 and M-CSF DuoSets were purchased
from R&D Systems, Abingdon, UK. The assays were per-
formed on conditioned media from cells that had been
stimulated with cytokines or patient sera for 24 h ac-
cording to the manufacturer’s instructions to determine
protein levels in conditioned media from treated MCs.
qRT-PCR
RNA was extracted from MCs treated with cytokines for
24 h using the RNeasy miniprep kit (Qiagen, Manches-
ter, UK) following the manufacturer’s instructions. The
RNA concentration was determined by Nanodrop and
200-500 ng RNA was transcribed into cDNA using either
the AffinityScript multi-temp cDNA synthesis kit (Agilent
Technologies, Cheshire, UK) following the manufacturer’s
Table 2 List of primers used for qRT-PCR
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instructions for 24 h cytokine treatments or the Primerde-
sign all-in-one Reverse Transcription mix (Primerdesign,
York, UK) following manufacturer’s instructions (for sera
and TGF-β1 blocking assays). qRT-PCR was performed
using the primers described in (Table 2) with the Brilliant
III Ultra-fast SYBR QPCR mastermix kit (Agilent Tech-
nologies) following the manufacturer’s instructions (for
24 h cytokine treatments) or the Primerdesign Precision-
PLUS qPCR Master Mix kit (for sera and TGF-β1 block-
ing assays). The geometric mean of tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation
protein Zeta (YWHAZ), β-actin (ACTB) and TUBB was
used as an internal reference control for normalisation
and used to calculate the ΔΔCt value.
Statistical analysis
Data are expressed as median [range] unless otherwise
stated. Statistical analysis was performed using Graph-
Pad Prism 7.01 software programme. Statistical signifi-
cance was evaluated using Friedman’s test (for paired
analyses) or Kruskal-Wallis test with Dunn’s post-hoc
test. A P value of less than 0.05 was considered to be
statistically significant.
Acknowledgements
The authors thank Professor Moin Saleem, University of Bristol, for providing
the conditionally immortalised mesangial cell line. The authors would also
like to thank colleagues within the UK’s ‘Experimental Arthritis Treatment
Centre for Children’ (www.EATC4Children.co.uk), the National Institute of
Health Research Alder Hey Clinical Research Facility for Experimental
Medicine, and in particular the Lupus Research Group, supported by LUPUS
UK, for their support and comments on this work.
Authors’ contributions
Conceptualization, RDW and MWB; Methodology, RDW; Investigation, RDW,
PD, and SJN; Writing – Original Draft, RDW; Writing – Review & Editing, RDW,
PD, SJN, and MWB; Funding Acquisition, MWB. All authors read and
approved the final manuscript.
Funding
This work was supported by the Alder Hey Children’s Kidney Fund, the UK’s
Experimental Arthritis Treatment Centre for Children (supported by Versus
Arthritis, Alder Hey Children’s NHS Foundation Trust, the Alder Hey Charity,
and the University of Liverpool), LUPUS UK, and the National Institute of
Health Research (NIHR) Alder Hey Clinical Research Facility for Experimental
Medicine.
Availability of data and materials
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
Ethics approval and consent to participate
All methods reported here were carried out in accordance with relevant
guidelines and regulations of the University of Liverpool. All experimental
protocols were reviewed and approved by the North West – Liverpool East
Research Ethics Committee (UK JSLE Cohort Study and Repository – REC: 06/
Q1502/77). Informed consent was obtained from all subjects, or if subjects
are under 18, from a parent and/or legal guardian.
Consent for publication
Written informed consent was obtained from the patient/parent or guardian
if under 18 years of age for publication of their anonymised details in this
manuscript. The consent forms are held by the Experimental Arthritis
Treatment Centre for Children (EATC4Children) and are available for review
by the Editor-in-Chief.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Women’s and Children’s Health, Institute of Translational
Medicine, University of Liverpool, member of Liverpool Health Partners,
Liverpool, UK. 2Department of Women and Children’s Health, Institute in the
Park, Alder Hey Children’s NHS Foundation Trust, Eaton Road, Liverpool L12
2AP, UK. 3Department of Paediatric Rheumatology, Alder Hey Children’s NHS
Foundation Trust, member of Liverpool Health Partners, Liverpool, UK.
Received: 29 July 2019 Accepted: 5 November 2019
References
1. Hersh AO, von Scheven E, Yazdany J, et al. Differences in long-term disease
activity and treatment of adult patients with childhood- and adult-onset
systemic lupus erythematosus. Arthritis Rheum. 2009;61:13–20. https://doi.
org/10.1002/art.24091.
2. Hoffman IE, Lauwerys BR, De Keyser F, et al. Juvenile-onset systemic lupus
erythematosus: different clinical and serological pattern than adult-onset
systemic lupus erythematosus. Ann Rheum Dis. 2009;68:412–5. https://doi.
org/10.1136/ard.2008.094813.
3. Mina R, Brunner HI. Pediatric lupus--are there differences in presentation,
genetics, response to therapy, and damage accrual compared with adult
lupus? Rheum Dis Clin N Am. 2010;36:53–80, vii-viii. https://doi.org/10.1016/j.
rdc.2009.12.012.
4. Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage
in the UK juvenile-onset systemic lupus Erythematosus cohort. Arthritis
Rheum. 2012;64:2356–65. https://doi.org/10.1002/art.34410.
5. Bagavant H, Fu SM. Pathogenesis of kidney disease in systemic lupus
erythematosus. Curr Opin Rheumatol. 2009;21:489–94. https://doi.org/10.
1097/BOR.0b013e32832efff1.
6. Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis.
Arthritis Res Ther. 2011;13:250. https://doi.org/10.1186/ar3528 2011/12/21.
7. Yang C, Glass WF. Expression of alpha-actinin-1 in human glomerular
mesangial cells in vivo and in vitro. Exp Biol Med (Maywood). 2008;233:689–
93. https://doi.org/10.3181/0710-RM-279 2008/04/11.
8. Yung S, Cheung KF, Zhang Q, et al. Anti-dsDNA antibodies bind to
mesangial annexin II in lupus nephritis. J Am Soc Nephrol. 2010;21:1912–27.
https://doi.org/10.1681/ASN.2009080805 2010/09/16.
9. Fenton K, Fismen S, Hedberg A, et al. Anti-dsDNA antibodies promote
initiation, and acquired loss of renal Dnase1 promotes progression of lupus
nephritis in autoimmune (NZBxNZW)F1 mice. PLoS One. 2009;4:e8474.
https://doi.org/10.1371/journal.pone.0008474 2009/12/29.
10. Abboud HE. Mesangial cell biology. Exp Cell Res. 2012;318:979–85. https://
doi.org/10.1016/j.yexcr.2012.02.025 2012/03/05.
11. Schlöndorff D. Roles of the mesangium in glomerular function. Kidney Int.
1996;49:1583–5.
12. Scindia YM, Deshmukh US, Bagavant H, et al. Adv Drug Deliv Rev. 2010;62:
1337–43. https://doi.org/10.1016/j.addr.2010.08.011 2010/09/07.
13. Hu W, Chen Y, Wang S, et al. Clinical-Morphological Features and Outcomes
of Lupus Podocytopathy. Clin J Am Soc Nephrol. 2016;11:585–92. https://
doi.org/10.2215/CJN.06720615 2016/03/16.
14. Tveita AA, Rekvig OP, Zykova SN. Increased glomerular matrix
metalloproteinase activity in murine lupus nephritis. Kidney Int. 2008;74:
1150–8. https://doi.org/10.1038/ki.2008.308 2008/07/02.
15. Floege J, Johnson RJ, Gordon K, et al. Increased synthesis of extracellular
matrix in mesangial proliferative nephritis. Kidney Int. 1991;40:477–88.
16. Pontillo A, Reis EC, Liphaus BL, et al. Inflammasome polymorphisms in
juvenile systemic lupus erythematosus. Autoimmunity. 2015;48:434–7.
https://doi.org/10.3109/08916934.2015.1064399 2015/07/16.
17. Postal M, Peliçari KO, Sinicato NA, et al. Th1/Th2 cytokine profile in
childhood-onset systemic lupus erythematosus. Cytokine. 2013;61:785–91.
https://doi.org/10.1016/j.cyto.2012.11.023 2013/01/17.
18. Rodero MP, Decalf J, Bondet V, et al. Detection of interferon alpha protein
reveals differential levels and cellular sources in disease. J Exp Med. 2017;
214:1547–55. https://doi.org/10.1084/jem.20161451 2017/04/18.
Wright et al. Journal of Inflammation           (2019) 16:22 Page 13 of 14
19. Yazici MU, Orhan D, Kale G, et al. Studying IFN-gamma, IL-17 and FOXP3 in
pediatric lupus nephritis. Pediatr Nephrol. 2014;29:853–62. https://doi.org/10.
1007/s00467-013-2695-1 2014/01/31.
20. Martin J, Knowlden J, Davies M, et al. Identification and independent
regulation of human mesangial cell metalloproteinases. Kidney Int. 1994;46:
877–85.
21. Martin J, Eynstone L, Davies M, et al. Induction of metalloproteinases by
glomerular mesangial cells stimulated by proteins of the extracellular matrix.
J Am Soc Nephrol. 2001;12:88–96.
22. Sinuani I, Beberashvili I, Averbukh Z, et al. Role of IL-10 in the progression of
kidney disease. World J Transplant. 2013;3:91–8. https://doi.org/10.5500/wjt.
v3.i4.91.
23. Coleman DL, Ruef C. Interleukin-6: an autocrine regulator of mesangial cell
growth. Kidney Int. 1992;41:604–6.
24. Sheng ZX, Yao H, Cai ZY. The role of miR-146b-5p in TLR4 pathway of
glomerular mesangial cells with lupus nephritis. Eur Rev Med Pharmacol Sci.
2018;22:1737–43.
25. Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin.
2007;45:27–37. https://doi.org/10.1097/AIA.0b013e318034194e.
26. Yung S, Zhang Q, Chau MK, et al. Distinct effects of mycophenolate mofetil
and cyclophosphamide on renal fibrosis in NZBWF1/J mice. Autoimmunity.
2015;48:471–87. https://doi.org/10.3109/08916934.2015.1054027 2015/06/23.
27. Bergijk EC, Van Alderwegen IE, Baelde HJ, et al. Differential expression of
collagen IV isoforms in experimental glomerulosclerosis. J Pathol. 1998;184:
307–15. https://doi.org/10.1002/(SICI)1096-9896(199803)184:3<307::AID-
PATH5>3.0.CO;2-W.
28. Nakajima M, Kawahara S, Sakagami Y, et al. Immunogold labelling of
cytokines in glomeruli in children with various renal diseases. Nephron.
1999;83:132–8. https://doi.org/10.1159/000045490.
29. Peutz-Kootstra CJ, Hansen K, De Heer E, et al. Differential expression of
laminin chains and anti-laminin autoantibodies in experimental lupus
nephritis. J Pathol. 2000;192:404–12. https://doi.org/10.1002/1096-
9896(2000)9999:9999<::AID-PATH707>3.0.CO;2-L.
30. Kaname S, Uchida S, Ogata E, et al. Autocrine secretion of transforming growth
factor-beta in cultured rat mesangial cells. Kidney Int. 1992;42:1319–27.
31. Yu J, Hu X, Yang Z, et al. Salt-inducible kinase 1 is involved in high glucose-
induced mesangial cell proliferation mediated by the ALK5 signaling
pathway. Int J Mol Med. 2013;32:151–7. https://doi.org/10.3892/ijmm.2013.
1377 2013/05/10.
32. Sarrab RM, Lennon R, Ni L, et al. Establishment of conditionally immortalized
human glomerular mesangial cells in culture, with unique migratory
properties. Am J Physiol Ren Physiol. 2011;301:F1131–8. https://doi.org/10.
1152/ajprenal.00589.2010 2011/06/08.
33. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial
validation of an updated version of the British Isles Lupus Assessment
Group's disease activity index for patients with systemic lupus
erythematosus. Rheumatology (Oxford). 2005;44:902–6. https://doi.org/10.
1093/rheumatology/keh624 2005/04/09.
34. Smith EMD, Yin P, Jorgensen AL, et al. Clinical predictors of proteinuric
remission following an LN flare - evidence from the UK JSLE cohort study.
Pediatr Rheumatol Online J. 2018;16:14. https://doi.org/10.1186/s12969-018-
0230-4 2018/02/23.
35. Matsuyama S, Iwadate M, Kondo M, et al. SB-431542 and Gleevec inhibit
transforming growth factor-beta-induced proliferation of human
osteosarcoma cells. Cancer Res. 2003;63:7791–8.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Wright et al. Journal of Inflammation           (2019) 16:22 Page 14 of 14
